FDA approves change in Claritin labeling

KENILWORTH, N.J. Schering-Plough on Tuesday announced that the Food and Drug Administration approved additional labeling for Claritin that emphasizes the allergy medicine is appropriate for use to help treat both indoor (perennial) and outdoor (seasonal) allergies.

“Schering-Plough is pleased that the FDA has approved the change to the Claritin label to help us to communicate to consumers that Claritin works hard to relieve both indoor and outdoor allergies,” stated John O’Mullane, vice president of research and development for Schering-Plough Consumer Health Care.